Evidence Level B Emerging Evidence

Persistent multisystem symptoms following acute SARS-CoV-2 infection — including fatigue, cognitive dysfunction ("brain fog"), sleep disturbance, and pain. A 2022 randomised controlled trial reported significant improvements in cognitive function, sleep, pain, and overall symptom burden after 40 HBOT sessions, with benefits sustained at one-year follow-up. The evidence base is currently anchored to a single research group; independent replication is awaited (HOT-LoCO trial in progress).

Treatment protocol

Protocol

Pressure

2.0 ATA

Duration

90 min

Sessions

Frequency

5×/week

Evidence basis: Zilberman-Itskovich et al., 2022 (RCT)

References:

25 26 27 28

See full citations on the references page.